Results 21 to 30 of about 15,231 (118)
Pattern of differential expression of costimulatory molecules in myeloma cell line MM1.R
T cells constantly recognise and eliminate circulating tumour cells. They require two signals in order to be activated: antigen presentation via TCR, and costimulatory interaction with different surface molecules of the B7 family, which may either ...
A. De la Cruz-Rosas +4 more
doaj +1 more source
Abstract Oral tolerance is a key feature of intestinal immunity, generating systemic tolerance to fed antigens. However, the molecular mechanism mediating oral tolerance remains unclear. In this study, we examined the role of the B7 family members of costimulatory molecules in the establishment of oral tolerance.
Fukaya, Tomohiro +12 more
openaire +3 more sources
. Cytotoxic/pro-apoptogenic effects of IFNα-induced dendritic cells (IFN-DCs) directed against Т-lymphocytes and NK cells were investigated in healthy donors.
T. V. Tyrinova +5 more
doaj +1 more source
Specific zinc finger‐induced methylation of PD‐L1 promoter inhibits its expression
DNA methylation of promoter regions is often associated with epigenetic silencing of gene expression, and DNA methyltransferase (DNMTs) has been used to suppress gene expression.
Xue Li +11 more
doaj +1 more source
Due to their ability to present foreign antigens and prime naïve T cells, macrophages, and dendritic cells (DCs) are referred to as professional antigen-presenting cells (APCs).
Dimitar B. Iliev +6 more
doaj +1 more source
Targeting WDR12 Unleashes T‐Cell‐Mediated Antitumor Activity in Melanoma by Destabilizing CD276
WDR12 cooperates with the chaperonin subunit CCT7 to maintain CD276 stability on tumor cells, suppressing T‐cell activity and promoting immune escape. SU14813, a small‐molecule WDR12 inhibitor, reduces CD276 stability and relieves CD276‐mediated T‐cell suppression.
Jie Pan +10 more
wiley +1 more source
Targeting KRAS for cancer therapy
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
A bandgap‐engineered PtxTey:Ag2Te quantum dot platform enables tunable NIR‐IIb emission for deep‐tissue imaging and mild photothermal therapy. Conjugation with αPD‐L1 confers dual tumor targeting and real‐time monitoring of PD‐L1 dynamics. Mild photothermal modulation induces immune reprogramming, enhancing checkpoint blockade efficacy and achieving ...
Jing Liu +9 more
wiley +1 more source
Experimental workflow of HER2/Neu‐targeted dendritic cell‐based chemo‐immunotherapy in a 4T1‐HER2 breast cancer xenograft model. ABSTRACT The discovery of tumor‐associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer ...
Cenk Serhan Özverel +4 more
wiley +1 more source
Extracellular vesicles (EVs) for immune therapy of cancer have both direct and indirect effects on immune cells. When taken up, the loaded antigen is presented by the host's dendritic cells (indirect). In this case, EV surface molecules like MHC‐peptide complexes on EVs are of minor importance. Here we show that removal of PD‐L1 from the surface of EVs
Loes Teeuwen +9 more
wiley +1 more source

